SCHEMBL3244769

SCHEMBL3244769

CCOC(=O)c1c[nH]c2c(=O)[nH]c3ccc(NS(=O)(=O)c4ccc([N+](=O)[O-])cc4)cc3c12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 5/20 0.54
MAPT P10636 4/20 0.47
HTT P42858 1/20 0.47
MEN1 O00255 6/20 0.45
KMT2A Q03164 6/20 0.45
ALDH1A1 P00352 3/20 0.45
PKM P14618 1/20 0.45
HPGD P15428 2/20 0.44
ALOX15 P16050 1/20 0.44
MAPK1 P28482 1/20 0.44
HSD17B10 Q99714 1/20 0.44
LMNA P02545 3/20 0.42
ALOX12 P18054 1/20 0.42
TP53 P04637 1/20 0.41
BRD4 O60885 1/20 0.41
CYP3A4 P08684 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3249004 0.91 HIF1A (0.51) HIF1AMAPTMEN1KMT2AALDH1A1
SCHEMBL3251174 0.89 HIF1A (0.52) HIF1AMAPTMEN1KMT2AALDH1A1
SCHEMBL3254022 0.89 HIF1A (0.52) HIF1AMAPTHTTMEN1KMT2A
SCHEMBL3251191 0.89 PKM (0.49) HIF1AMAPTHTTMEN1KMT2A
SCHEMBL3255461 0.89 BRD4 (0.52) HIF1AMAPTMEN1KMT2AALDH1A1
SCHEMBL3252062 0.88 MEN1 (0.50) HIF1AMAPTMEN1KMT2AALDH1A1
SCHEMBL3254038 0.88 BRD4 (0.55) HIF1AMAPTHTTMEN1KMT2A
SCHEMBL3254000 0.88 LMNA (0.53) HIF1AMAPTHTTMEN1KMT2A
SCHEMBL3255189 0.87 BRD4 (0.55) HIF1AMAPTMEN1KMT2AALDH1A1
SCHEMBL3255981 0.87 HIF1A (0.49) HIF1AMAPTHTTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899335-B1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PF MEDICAMENT (FR) 2010-05-19 EP claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 HIF1A 974/4885MAPT 734/4885HTT 2443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.